Boston, MA -- (SBWIRE) -- 11/01/2013 -- At winstonsmallcap.com we focus on undervalued companies trading under $5. Right now the markets are surging and we are seeing an opportunity in micro-cap companies like we have never seen before. Let have a Look on: SK3 Group Inc(OTCMKTS:SKTO), Merck & Co., Inc.(NYSE:MRK), Sonus Networks, Inc.(NASDAQ:SONS), Generex Biotechnology Corporation(OTCMKTS:GNBT)
SK3 Group Inc (OTCMKTS:SKTO) opened its shares at the price of $0.02 for the day. Its closing price was $0.0155 after gaining +3.33% for the day. The company traded with the total volume of 9.19 million shares, while its average trading volume remained 12.53 million shares. The beta of SKTO stands at 30.18. SK3 Group, Inc., through its subsidiaries, offers a range of healthcare services in the United States.
For How Long SKTO will Fight for Profitability? Read This Trend Analysis report
Merck & Co., Inc. (NYSE:MRK) percentage change plunged -0.33% to close at $45.09 with the total traded volume of 14.99 million shares, and average volume of 15.11 million. The 52 week range of the stock remained $40.02 - $50.16, while its day lowest price was $45.09 and it hit its day highest price at $45.46. Merck & Co., Inc. provides various health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products worldwide.
Has MRK Found The Bottom And Ready To Gain Momentum? Find Out Here
Sonus Networks, Inc. (NASDAQ:SONS) started its trading session with the price of $3.05 and closed at $2.99 by scoring -1.64%. SONS’s stocks traded with total volume of 4.21 million shares, while the average trading volume remained 1.57 million shares. The beta of SONS stands at 1.72. Day range of the stock was $2.82 -$3.05. Sonus Networks, Inc. provides networked solutions for communications service providers and enterprises in the United States, Europe, the Middle East, Africa, and the Asia Pacific.
Why Should Investors Buy SONS After the Recent Fall? Just Go Here and Find Out
Generex Biotechnology Corporation (OTCMKTS:GNBT) ended its day at the price of $0.0300 after opening at $0.03. Stock traded during its last trading session with the total volume of 1.29 million shares, as compared to its average volume of 1.86 million shares. Generex Biotechnology Corporation, a development stage company, is engaged in the research, development, and commercialization of drug delivery systems and technologies for metabolic and immunological diseases.
Is GNBT Buy After The Recent Price Movement? Find Out Here
Here at Winston we focus on undervalued companies trading under $5. Right now the markets are surging and we are seeing an opportunity in micro-cap companies like we have never seen before. We focus on companies that we feel are trading at a discount to the market for various reasons. Enter your email and track our performance! We are sure you won’t be disappointed.
http://winstonsmallcap.com/ and its owners, and their affiliates, directors and officers, and immediate family members, are hereafter collectively referred to as “WSC” or “we” or “us” or “our”). WSC publishes information (the “Information”) about publicly traded companies (the “Profiled Company” or the “Profiled Companies”) which has been obtained from various sources including publicly available sources on the internet. WSC does not undertake any due diligence or investigation of the Information it obtains or publishes.
Read Full Disclaimer at: http://winstonsmallcap.com/disclaimer
Copyright © 2005-2013 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)